{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18","upperLimit":"75","value":"31"},{"groupId":"OG001","lowerLimit":"18","upperLimit":"146","value":"48"},{"groupId":"OG002","lowerLimit":"20","upperLimit":"98","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"72"}],"units":"Participants"}],"description":"The definition of feasibility is: Enrollment onto study, genomic profile, analysis and report generation completed, tumor board held with treatment decision, treatment review completed, start of treatment, and completion of 1 cycle of therapy.","dispersionType":"Full Range","groups":[{"description":"Subjects on study with a diagnosis of Neuroblastoma","id":"OG000","title":"Neuroblastoma"},{"description":"Subjects on study with a diagnosis of a CNS Tumor which included, but was not limited to, Ependymoma, Glioblastoma, Diffuse Midline Glioma, and Other CNS Tumors.","id":"OG001","title":"CNS Tumors"},{"description":"Subjects on study with a diagnosis of a rare solid tumor which included, but was not limited to, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, and Other Rare Tumors.","id":"OG002","title":"Rare Tumors"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"2 years","title":"Days to Treatment Will be Used in Order to Determine Feasibility of Using Tumor Samples to Assess Genomic Sequencing Using Predictive Modeling to Make Real-time Treatment Decisions for Children With Relapsed/Refractory Cancers.","type":"PRIMARY","unitOfMeasure":"Days"}